The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

被引：17

作者：

Ferraldeschi, Roberta ^{[1
,2
]}

Newman, William G. ^{[2
]}

机构：

[1] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England

[2] Univ Manchester, MAHSC, St Marys Hosp, Genet Med, Oxford Rd, Manchester M13 9WL, Lancs, England

来源：

PHARMACEUTICALS | 2010年 / 3卷 / 04期

关键词：

tamoxifen; CYP2D6; genotyping; breast cancer;

D O I：

10.3390/ph3041122

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.

引用

页码：1122 / 1138

页数：17

共 63 条

[41] Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases [J].

Nishiyama, T ;

Ogura, K ;

Nakano, H ;

Ohnuma, T ;

Kaku, T ;

Hiratsuka, A ;

Muro, K ;

Watabe, T .

BIOCHEMICAL PHARMACOLOGY, 2002, 63 (10) :1817-1830

[42] Pharmacogenetics of human cytosolic sulfotransferases [J].

Nowell, S ;

Falany, CN .

ONCOGENE, 2006, 25 (11) :1673-1678

[43] Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients [J].

Nowell, SA ;

Ahn, JY ;

Rae, JM ;

Scheys, JO ;

Trovato, A ;

Sweeney, C ;

MacLeod, SL ;

Kadlubar, FF ;

Ambrosone, CB .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 91 (03) :249-258

[44] Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen [J].

Ntukidem, N. I. ;

Nguyen, A. T. ;

Stearns, V. ;

Rehman, M. ;

Schott, A. ;

Skaar, T. ;

Jin, Y. ;

Blanche, P. ;

Li, L. ;

Lemler, S. ;

Hayden, J. ;

Krauss, R. M. ;

Desta, Z. ;

Flockhart, D. A. ;

Hayes, D. F. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) :702-710

[45] Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4 [J].

Ogura, K ;

Ishikawa, Y ;

Kaku, T ;

Nishiyama, T ;

Ohnuma, T ;

Muro, K ;

Hiratsuka, A .

BIOCHEMICAL PHARMACOLOGY, 2006, 71 (09) :1358-1369

[46] Genetic Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 Are not Associated With Prognosis, Endometrial Thickness, or Bone Mineral Density in Japanese Breast Cancer Patients Treated With Adjuvant Tamoxifen [J].

Okishiro, Masatsugu ;

Taguchi, Tetsuya ;

Kim, Seung Jin ;

Shimazu, Kenzo ;

Tamaki, Yasuhiro ;

Noguchi, Shinzaburo .

CANCER, 2009, 115 (05) :952-961

[47] Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy [J].

Onitilo, Adedayo A. ;

McCarty, Catherine A. ;

Wilke, Russell A. ;

Glurich, Ingrid ;

Engel, Jessica M. ;

Flockhart, David A. ;

Nguyen, Anne ;

Li, Lang ;

Mi, Deming ;

Skaar, Todd C. ;

Jin, Yan .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (03) :643-650

[48] Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer:: A modeling analysis [J].

Punglia, Rinaa S. ;

Burstein, Harold J. ;

Winer, Eric P. ;

Weeks, Jane C. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (09) :642-648

[49] Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients [J].

Rae, J. M. ;

Sikora, M. J. ;

Henry, N. L. ;

Li, L. ;

Kim, S. ;

Oesterreich, S. ;

Skaar, T. C. ;

Nguyen, A. T. ;

Desta, Z. ;

Storniolo, A. M. ;

Flockhart, D. A. ;

Hayes, D. F. ;

Stearns, V. .

PHARMACOGENOMICS JOURNAL, 2009, 9 (04) :258-264

[50] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment [J].

Ramon y Cajal, T. ;

Altes, A. ;

Pare, L. ;

del Rio, E. ;

Alonso, C. ;

Barnadas, A. ;

Baiget, M. .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) :33-38

← 1 2 3 4 5 6 7 →